{
    "symbol": "THMO",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-31 16:19:02",
    "content": " The ReadyStart cGMP suites are expected to be available for customers in the second and third quarter of this year and, once fully leased, are expected to generate an additional annual revenue in the range of $10 million to $16 million. Net revenues were $10.5 million for the year ended December 31, 2022, up 13% from last year. Gross profit for the year ended December 31, 2022 was $2.7 million or 26% of net revenues compared to $3.5 million or 38% of net revenues for 2021. Selling, general and administrative expenses were $7.2 million for the year ended December 31, 2022, as compared to $8.5 million for 2021. Research and development expenses were $1.7 million for the year ended December 31, 2022, as compared to $2.2 million for 2021. For the year ended December 31, 2022, the company recorded a comprehensive loss attributable to common stockholders of $11.2 million or $20.45 per share based on approximately 550,000 of weighted average shares outstanding. This compares to comprehensive net loss of $11.4 million or $43.41 per share based on approximately 262,000 weighted average shares outstanding for the year ended December 31, 2021."
}